Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 42, Issue 5, 2015, Pages 553-571

  Shah, Dhaval K ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

ADME; Biologics; Immunogenicity; Novel scaffold; Pharmacodynamic; Pharmacokinetic; Protein therapeutics; Toxicity

Indexed keywords

ANTIBODY CONJUGATE; BIOLOGICAL PRODUCT; LIGAND; MOLECULAR SCAFFOLD; MONOCLONAL ANTIBODY; ANTIBODY; PROTEIN;

ARTICLE; BIOLOGICAL THERAPY; BIOMIMETICS; DRUG ABSORPTION; DRUG BINDING; DRUG DESIGN; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SCREENING; DRUG TARGETING; HUMAN; IMMUNOGENICITY; NONHUMAN; PHARMACODYNAMIC PARAMETERS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; ANIMAL; BIOLOGICAL MODEL;

ANIMALS; ANTIBODIES; HUMANS; IMMUNOCONJUGATES; MODELS, BIOLOGICAL; PROTEINS;

EID: 84942501025     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-015-9447-8     Document Type: Article

References (85)

1. Leader B, Baca QJ, Golan DE (2008) Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov 7(1):21–39. doi:10.1038/nrd2399
2. Beck A, Wurch T, Bailly C, Corvaia N (2010) Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 10(5):345–352. doi:10.1038/nri2747
3. Skrlec K, Strukelj B, Berlec A (2015) Non-immunoglobulin scaffolds: a focus on their targets. Trends Biotechnol 33(7):408–418. doi:10.1016/j.tibtech.2015.03.012
4. Wurch T, Pierre A, Depil S (2012) Novel protein scaffolds as emerging therapeutic proteins: from discovery to clinical proof-of-concept. Trends Biotechnol 30(11):575–582. doi:10.1016/j.tibtech.2012.07.006
5. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B, Fox JA, Presta LG (2001) High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 276(9):6591–6604. doi:10.1074/jbc.M009483200
6. Oganesyan V, Gao C, Shirinian L, Wu H, Dall’Acqua WF (2008) Structural characterization of a human Fc fragment engineered for lack of effector functions. Acta Crystallogr D Biol Crystallogr 64(Pt 6):700–704. doi:10.1107/S0907444908007877
7. Dall’Acqua WF, Kiener PA, Wu H (2006) Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 281(33):23514–23524. doi:10.1074/jbc.M604292200
8. Strop P, Delaria K, Foletti D, Witt JM, Hasa-Moreno A, Poulsen K, Casas MG, Dorywalska M, Farias S, Pios A, Lui V, Dushin R, Zhou D, Navaratnam T, Tran TT, Sutton J, Lindquist KC, Han B, Liu SH, Shelton DL, Pons J, Rajpal A (2015) Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading. Nat Biotechnol 33(7):694–696. doi:10.1038/nbt.3274
9. Agarwal P, Bertozzi CR (2015) Site-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development. Bioconjugate chem 26(2):176–192. doi:10.1021/bc5004982
10. Zhou Q, Kim J (2015) Advances in the development of site-specific antibody-drug conjugation. Anticancer Agents Med Chem 15(7):828–836
11. Alewine C, Hassan R, Pastan I (2015) Advances in anticancer immunotoxin therapy. Oncologist 20(2):176–185. doi:10.1634/theoncologist.2014-0358
12. List T, Neri D (2013) Immunocytokines: a review of molecules in clinical development for cancer therapy. Clinical Pharmacol: Adv Appl 5:29–45. doi:10.2147/CPAA.S49231
13. Kraeber-Bodere F, Bodet-Milin C, Rousseau C, Eugene T, Pallardy A, Frampas E, Carlier T, Ferrer L, Gaschet J, Davodeau F, Gestin JF, Faivre-Chauvet A, Barbet J, Cherel M (2014) Radioimmunoconjugates for the treatment of cancer. Semin Oncol 41(5):613–622. doi:10.1053/j.seminoncol.2014.07.004
14. DiGiammarino E, Ghayur T, Liu J (2012) Design and generation of DVD-Ig molecules for dual-specific targeting. Methods Mol Biol 899:145–156. doi:10.1007/978-1-61779-921-1_9
15. Zanin M, Keck ZY, Rainey GJ, Lam CY, Boon AC, Rubrum A, Darnell D, Wong SS, Griffin Y, Xia J, Webster RG, Webby R, Johnson S, Foung S (2015) An anti-H5N1 influenza virus FcDART antibody is a highly efficacious therapeutic agent and prophylactic against H5N1 influenza virus infection. J Virol 89(8):4549–4561. doi:10.1128/JVI.00078-15
16. Buie LW, Pecoraro JJ, Horvat TZ, Daley RJ (2015) Blinatumomab: a first-in-class bispecific T-cell engager for precursor B-cell acute lymphoblastic leukemia. Ann Pharmacother. doi:10.1177/1060028015588555
17. Caravella J, Lugovskoy A (2010) Design of next-generation protein therapeutics. Curr Opin Chem Biol 14(4):520–528. doi:10.1016/j.cbpa.2010.06.175
18. Lehmann A (2008) Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery. Expert Opinion on Biol Therapy 8(8):1187–1199. doi:10.1517/14712598.8.8.1187
19. Kariolis MS, Kapur S, Cochran JR (2013) Beyond antibodies: using biological principles to guide the development of next-generation protein therapeutics. Curr Opin Biotechnol 24(6):1072–1077. doi:10.1016/j.copbio.2013.03.017
20. Lindzen M, Carvalho S, Starr A, Ben-Chetrit N, Pradeep CR, Kostler WJ, Rabinkov A, Lavi S, Bacus SS, Yarden Y (2012) A recombinant decoy comprising EGFR and ErbB-4 inhibits tumor growth and metastasis. Oncogene 31(30):3505–3515. doi:10.1038/onc.2011.518
21. Al-Halafi AM (2014) Vascular endothelial growth factor trap-eye and trap technology: aflibercept from bench to bedside. Oman J Ophthalmol 7(3):112–115. doi:10.4103/0974-620X.142591
22. Gabay C (2003) IL-1 trap. Regeneron/novartis. Curr Opin Investig Drugs 4(5):593–597
23. Foss FM (2000) DAB(389)IL-2 (denileukin diftitox, ONTAK): a new fusion protein technology. Clin Lymphoma 1(Suppl 1):S27–31
24. Low SC, Nunes SL, Bitonti AJ, Dumont JA (2005) Oral and pulmonary delivery of FSH-Fc fusion proteins via neonatal Fc receptor-mediated transcytosis. Hum Reprod 20(7):1805–1813. doi:10.1093/humrep/deh896
25. Pridgen EM, Alexis F, Kuo TT, Levy-Nissenbaum E, Karnik R, Blumberg RS, Langer R, Farokhzad OC (2013) Transepithelial transport of Fc-targeted nanoparticles by the neonatal fc receptor for oral delivery. Sci Transl Med 5(213):213ra167. doi:10.1126/scitranslmed.3007049
26. Wu F, Bhansali SG, Law WC, Bergey EJ, Prasad PN, Morris ME (2012) Fluorescence imaging of the lymph node uptake of proteins in mice after subcutaneous injection: molecular weight dependence. Pharm Res 29(7):1843–1853. doi:10.1007/s11095-012-0708-6
27. Deng R, Meng YG, Hoyte K, Lutman J, Lu Y, Iyer S, DeForge LE, Theil FP, Fielder PJ, Prabhu S (2012) Subcutaneous bioavailability of therapeutic antibodies as a function of FcRn binding affinity in mice. mAbs 4(1):101–109. doi:10.4161/mabs.4.1.18543
28. Zheng Y, Tesar DB, Benincosa L, Birnbock H, Boswell CA, Bumbaca D, Cowan KJ, Danilenko DM, Daugherty AL, Fielder PJ, Grimm HP, Joshi A, Justies N, Kolaitis G, Lewin-Koh N, Li J, McVay S, O’Mahony J, Otteneder M, Pantze M, Putnam WS, Qiu ZJ, Ruppel J, Singer T, Stauch O, Theil FP, Visich J, Yang J, Ying Y, Khawli LA, Richter WF (2012) Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration. mAbs 4(2):243–255. doi:10.4161/mabs.4.2.19387
29. Supersaxo A, Hein WR, Steffen H (1990) Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res 7(2):167–169
30. Fathallah AM, Turner MR, Mager DE, Balu-Iyer SV (2015) Effects of hypertonic buffer composition on lymph node uptake and bioavailability of rituximab, after subcutaneous administration. Biopharm Drug Dispos 36(2):115–125. doi:10.1002/bdd.1925
31. Kim H, Robinson SB, Csaky KG (2009) FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye. Mol Vis 15:2803–2812
32. Shah DK, Betts AM (2013) Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human. mAbs 5(2):297–305. doi:10.4161/mabs.23684
33. Rippe B, Haraldsson B (1987) Fluid and protein fluxes across small and large pores in the microvasculature. Application of two-pore equations. Acta Physiol Scand 131(3):411–428. doi:10.1111/j.1748-1716.1987.tb08257.x
34. Boswell CA, Tesar DB, Mukhyala K, Theil FP, Fielder PJ, Khawli LA (2010) Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjugate Chem 21(12):2153–2163. doi:10.1021/bc100261d
35. Garg A, Balthasar JP (2007) Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn 34(5):687–709. doi:10.1007/s10928-007-9065-1
36. Chen N, Wang W, Fauty S, Fang Y, Hamuro L, Hussain A, Prueksaritanont T (2014) The effect of the neonatal Fc receptor on human IgG biodistribution in mice. mAbs 6(2):502–508. doi:10.4161/mabs.27765
37. Cooper PR, Ciambrone GJ, Kliwinski CM, Maze E, Johnson L, Li Q, Feng Y, Hornby PJ (2013) Efflux of monoclonal antibodies from rat brain by neonatal Fc receptor, FcRn. Brain Res 1534:13–21. doi:10.1016/j.brainres.2013.08.035
38. Vugmeyster Y, DeFranco D, Szklut P, Wang Q, Xu X (2010) Biodistribution of [125I]-labeled therapeutic proteins: application in protein drug development beyond oncology. J Pharm Sci 99(2):1028–1045. doi:10.1002/jps.21855
39. Schmidt MM, Wittrup KD (2009) A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 8(10):2861–2871. doi:10.1158/1535-7163.MCT-09-0195
40. Weinstein JN, van Osdol W (1992) Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the “binding site barrier”. Cancer Res 52(9 Suppl):2747s–2751s
41. Yu YJ, Zhang Y, Kenrick M, Hoyte K, Luk W, Lu Y, Atwal J, Elliott JM, Prabhu S, Watts RJ, Dennis MS (2011) Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med 3(84):84ra44. doi:10.1126/scitranslmed.3002230
42. Hamilton S, Odili J, Wilson GD, Kupsch JM (2002) Reducing renal accumulation of single-chain Fv against melanoma-associated proteoglycan by coadministration of L-lysine. Melanoma Res 12(4):373–379
43. Lin K, Tibbitts J (2012) Pharmacokinetic considerations for antibody drug conjugates. Pharm Res 29(9):2354–2366. doi:10.1007/s11095-012-0800-y
44. Shah DK, Haddish-Berhane N, Betts A (2012) Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin. J Pharmacokinet Pharmacodyn 39(6):643–659. doi:10.1007/s10928-012-9276-y
45. Singh AP, Shin YG, Shah DK (2015) Application of pharmacokinetic-pharmacodynamic modeling and simulation for antibody-drug conjugate development. Pharm Res. doi:10.1007/s11095-015-1626-1
46. Chudasama VL, Zutshi A, Singh P, Abraham AK, Mager DE, Harrold JM (2015) Simulations of site-specific target-mediated pharmacokinetic models for guiding the development of bispecific antibodies. J Pharmacokinet Pharmacodyn 42(1):1–18. doi:10.1007/s10928-014-9401-1
47. Norden AG, Lapsley M, Lee PJ, Pusey CD, Scheinman SJ, Tam FW, Thakker RV, Unwin RJ, Wrong O (2001) Glomerular protein sieving and implications for renal failure in Fanconi syndrome. Kidney Int 60(5):1885–1892. doi:10.1046/j.1523-1755.2001.00016.x
48. Newkirk MM, Novick J, Stevenson MM, Fournier MJ, Apostolakos P (1996) Differential clearance of glycoforms of IgG in normal and autoimmune-prone mice. Clin Exp Immunol 106(2):259–264
49. Deng R, Jin F, Prabhu S, Iyer S (2012) Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development? Expert Opin on Drug Metab Toxicol 8(2):141–160. doi:10.1517/17425255.2012.643868
50. Huang L, Biolsi S, Bales KR, Kuchibhotla U (2006) Impact of variable domain glycosylation on antibody clearance: an LC/MS characterization. Anal Biochem 349(2):197–207. doi:10.1016/j.ab.2005.11.012
51. Yeung YA, Leabman MK, Marvin JS, Qiu J, Adams CW, Lien S, Starovasnik MA, Lowman HB (2009) Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J Immunol 182(12):7663–7671. doi:10.4049/jimmunol.0804182
52. Suzuki T, Ishii-Watabe A, Tada M, Kobayashi T, Kanayasu-Toyoda T, Kawanishi T, Yamaguchi T (2010) Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol 184(4):1968–1976. doi:10.4049/jimmunol.0903296
53. Czajkowsky DM, Hu J, Shao Z, Pleass RJ (2012) Fc-fusion proteins: new developments and future perspectives. EMBO Mol Med 4(10):1015–1028. doi:10.1002/emmm.201201379
54. Sand KM, Bern M, Nilsen J, Noordzij HT, Sandlie I, Andersen JT (2014) Unraveling the Interaction between FcRn and albumin: opportunities for design of albumin-based therapeutics. Front Immunol 5:682. doi:10.3389/fimmu.2014.00682
55. Mager DE, Jusko WJ (2001) General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 28(6):507–532
56. Peletier LA, Gabrielsson J (2012) Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification. J Pharmacokinet Pharmacodyn 39(5):429–451. doi:10.1007/s10928-012-9260-6
57. Vugmeyster Y, Szklut P, Wensel D, Ross J, Xu X, Awwad M, Gill D, Tchistiakov L, Warner G (2011) Complex pharmacokinetics of a humanized antibody against human amyloid beta peptide, anti-abeta Ab2, in nonclinical species. Pharm Res 28(7):1696–1706. doi:10.1007/s11095-011-0405-x
58. Bumbaca D, Wong A, Drake E, Reyes AE 2nd, Lin BC, Stephan JP, Desnoyers L, Shen BQ, Dennis MS (2011) Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4. mAbs 3(4):376–386
59. Hotzel I, Theil FP, Bernstein LJ, Prabhu S, Deng R, Quintana L, Lutman J, Sibia R, Chan P, Bumbaca D, Fielder P, Carter PJ, Kelley RF (2012) A strategy for risk mitigation of antibodies with fast clearance. mAbs 4(6):753–760. doi:10.4161/mabs.22189
60. Rehlaender BN, Cho MJ (1998) Antibodies as carrier proteins. Pharm Res 15(11):1652–1656
61. Ducourau E, Mulleman D, Paintaud G, Miow Lin DC, Lauferon F, Ternant D, Watier H, Goupille P (2011) Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Therapy 13(3):R105. doi:10.1186/ar3386
62. Brinks V, Weinbuch D, Baker M, Dean Y, Stas P, Kostense S, Rup B, Jiskoot W (2013) Preclinical models used for immunogenicity prediction of therapeutic proteins. Pharm Res 30(7):1719–1728. doi:10.1007/s11095-013-1062-z
63. Bryson CJ, Jones TD, Baker MP (2010) Prediction of immunogenicity of therapeutic proteins: validity of computational tools. BioDrugs: Clin Immunother Biopharm Gene Therapy 24(1):1–8. doi:10.2165/11318560-000000000-00000
64. Han TH, Zhao B (2014) Absorption, distribution, metabolism, and excretion considerations for the development of antibody-drug conjugates. Drug Metab Dispos: Biol Fate Chem 42(11):1914–1920. doi:10.1124/dmd.114.058586
65. Mack F, Ritchie M, Sapra P (2014) The next generation of antibody drug conjugates. Semin Oncol 41(5):637–652. doi:10.1053/j.seminoncol.2014.08.001
66. Hager T, Spahr C, Xu J, Salimi-Moosavi H, Hall M (2013) Differential enzyme-linked immunosorbent assay and ligand-binding mass spectrometry for analysis of biotransformation of protein therapeutics: application to various FGF21 modalities. Anal Chem 85(5):2731–2738. doi:10.1021/ac303203y
67. Kaur S, Xu K, Saad OM, Dere RC, Carrasco-Triguero M (2013) Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics. Bioanalysis 5(2):201–226. doi:10.4155/bio.12.299
68. Ezan E, Becher F, Fenaille F (2014) Assessment of the metabolism of therapeutic proteins and antibodies. Expert Opin On Drug Metab Toxicol 10(8):1079–1091. doi:10.1517/17425255.2014.925878
69. Wang SJ, Wu ST, Gokemeijer J, Fura A, Krishna M, Morin P, Chen G, Price K, Wang-Iverson D, Olah T, Weiner R, Tymiak A, Jemal M (2012) Attribution of the discrepancy between ELISA and LC-MS/MS assay results of a PEGylated scaffold protein in post-dose monkey plasma samples due to the presence of anti-drug antibodies. Anal Bioanal Chem 402(3):1229–1239. doi:10.1007/s00216-011-5527-9
70. Abuqayyas L, Balthasar JP (2012) Pharmacokinetic mAb-mAb interaction: anti-VEGF mAb decreases the distribution of anti-CEA mAb into colorectal tumor xenografts. AAPS J 14(3):445–455. doi:10.1208/s12248-012-9357-2
71. Walsh G (2014) Biopharmaceutical benchmarks 2014. Nat Biotechnol 32(10):992–1000. doi:10.1038/nbt.3040
72. Jusko WJ (2013) Moving from basic toward systems pharmacodynamic models. J Pharm Sci 102(9):2930–2940. doi:10.1002/jps.23590
73. Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ (2010) The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 9(4):325–338. doi:10.1038/nrd3003
74. Yan M (2011) Therapeutic promise and challenges of targeting DLL4/NOTCH1. Vasc Cell 3:17. doi:10.1186/2045-824X-3-17
75. Goodyear M (2006) Learning from the TGN1412 trial. BMJ 332(7543):677–678. doi:10.1136/bmj.38797.635012.47
76. Santostefano MJ, Kirchner J, Vissinga C, Fort M, Lear S, Pan WJ, Prince PJ, Hensley KM, Tran D, Rock D, Vargas HM, Narayanan P, Jawando R, Rees W, Reindel JF, Reynhardt K, Everds N (2012) Off-target platelet activation in macaques unique to a therapeutic monoclonal antibody. Toxicol Pathol 40(6):899–917. doi:10.1177/0192623312444029
77. Holland MC, Wurthner JU, Morley PJ, Birchler MA, Lambert J, Albayaty M, Serone AP, Wilson R, Chen Y, Forrest RM, Cordy JC, Lipson DA, Bayliffe AI (2013) Autoantibodies to variable heavy (VH) chain Ig sequences in humans impact the safety and clinical pharmacology of a VH domain antibody antagonist of TNF-alpha receptor 1. J Clin Immunol 33(7):1192–1203. doi:10.1007/s10875-013-9915-0
78. Lon HK, Liu D, Jusko WJ (2012) Pharmacokinetic/pharmacodynamic modeling in inflammation. Crit Rev Biomed Eng 40(4):295–312
79. Tabrizi M, Bornstein GG, Suria H (2010) Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. AAPS J 12(1):33–43. doi:10.1208/s12248-009-9157-5
80. Lammerts van Bueren JJ, Bleeker WK, Bogh HO, Houtkamp M, Schuurman J, van de Winkel JG, Parren PW (2006) Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. Cancer Res 66(15):7630–7638. doi:10.1158/0008-5472.CAN-05-4010
81. Shah DK, Betts AM (2012) Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn 39(1):67–86. doi:10.1007/s10928-011-9232-2
82. Kern SE (2012) Why your new cancer biomarker may never work: recurrent patterns and remarkable diversity in biomarker failures. Cancer Res 72(23):6097–6101. doi:10.1158/0008-5472.CAN-12-3232
83. Betts AM, Clark TH, Yang J, Treadway JL, Li M, Giovanelli MA, Abdiche Y, Stone DM, Paralkar VM (2010) The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis. J Pharmacol Exp Therap 333(1):2–13. doi:10.1124/jpet.109.164129
84. Luu KT, Bergqvist S, Chen E, Hu-Lowe D, Kraynov E (2012) A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting target-mediated drug disposition. J Pharmacol Exp Therap 341(3):702–708. doi:10.1124/jpet.112.191999
85. Bender BC, Schaedeli-Stark F, Koch R, Joshi A, Chu YW, Rugo H, Krop IE, Girish S, Friberg LE, Gupta M (2012) A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer. Cancer Chemother Pharmacol 70(4):591–601. doi:10.1007/s00280-012-1934-7